tbuckley/cabot-search huggingface dataset:
Five-year survival data in newly diagnosed glioblastoma treated with radiotherapy along with concurrent and adjuvant temozolomide
Authors: T. Wadasadawala, R. Jalali, A. Munshi, T. Gupta, N. Kalyani, H. Menon, R. Sarin, A. Goel
Journal: Journal of Clinical Oncology (2009)

e13009 Background: We report 5-year survival data in patients with newly diagnosed glioblastoma treated with radiotherapy along with concurrent and adjuvant temozolomide (TMZ). Methods: Between March 2001 to April 2008, 81 patients with newly diagnosed histopathologically proven glioblastoma underwent surgery followed by external radiotherapy to a total dose of 60 Gy in 30 fractions over 6 weeks. Concurrent oral TMZ (75 mg/m2) was given daily with RT followed by adjuvant TMZ for 5 days every 28 days for six cycles (150 mg/m2 for the first cycle and 200 mg/m2 for rest of the cycles). Patients were monitored clinicoradiologically as per standard practice. Results: Patients aged between 11–73 years with a median age of 49 years (60 males, 21 females). Forty per cent of patients underwent a gross total resection of tumour, 44% had partial resection, and 16% an open or stereotactic biopsy only. 79% of the patients had a post-operative Karnofsky Performance Score (KPS) of &gt;80. All six adjuvant cycles were completed in 68%. The 2-, 3-, 4-, and 5-year survival was 34%, 24%, 11%, and 11%, respectively (95% CI 14.03–21.96). The median overall and progression-free survival was 18 (2–92 months) and 16 months (2–72 months), respectively. On multivariate analysis, completion of all six cycles of adjuvant TMZ was associated with significantly better survival (p = 0.000). Neurological performance score (NPS) of 2–3 (p = 0.06) and Recursive Partitioning Analysis class V (p = 0.093) showed a trend towards poorer outcome. Treatment was generally well tolerated with only 2.5% of patients developing grade 3 anemia, leucopoenia, and neutropenia. Grade 3 or 4 thrombocytopenia was seen in 5% patients. Conclusions: Concurrent radiotherapy and TMZ followed by adjuvant TMZ results in encouraging survival even at a long follow-up. No significant financial relationships to disclose.
P196 A Local Domiciliary Non-invasive Ventilation (NIV) Service Reduces Length of Hospital Stay for Patients Unable to Wean From NIV: Abstract P196 Table 1
Authors: A Lane, S Harlow, P Murray
Journal: Thorax (2015)

<h3>Background</h3> NIV is a clinically proven treatment for acute hypercapnic respiratory failure.<sup>1</sup> Most patients are fully weaned from NIV before discharge from hospital but some with chronic ventilatory failure require long term NIV at home. Historically, these patients would need to wait for inpatient transfer to a tertiary centre for NIV titration. Due to the high demand for tertiary centre beds, this could take days to weeks. By this time, patients would frequently be optimised and stable on domiciliary NIV settings and only require transfer for equipment issue. A local domiciliary NIV service was commissioned in April 2012 to provide an integrated secondary care and community service closer to home and to reduce delayed discharge. <h3>Method</h3> Data were collected prospectively from 83 consecutive patients between October 2006 and May 2014 (395.6 weeks) from patients on a respiratory ward, unable to fully wean and requiring domiciliary NIV on discharge. <h3>Results</h3> See Table 1. <h3>Discussion</h3> Length of stay was reduced by an average of 4 days after the local domiciliary NIV service was initiated. Although this difference did not reach statistical significance it is certainly clinically significant, with huge pressure on clinicians to discharge patients in a timely manner. By managing the majority of these patients locally, it is hoped that the resources of the tertiary centres would be freed up to accept the very complex cases that still require tertiary centre input. <h3>Conclusion</h3> The provision of a local Domiciliary NIV service reduces length of stay by reducing waiting times for inpatient transfer to tertiary centres. <h3>Reference</h3> 1 Royal College of Physicians, British Thoracic Society, Intensive Care Society. <i>Chronic obstructive pulmonary disease: non-invasive ventilation with bi-phasic positive airways pressure in the management of patients with acute type 2 respiratory failure</i>. Concise Guidance to Good Practice series, No 11. London: RCP, 2008
A Brief Use of Imatinib Immediately Before Hematopoietic Stem Cell Transplantation (HSCT) in Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04
Authors: Atsushi Manabe, Hirohide Kawasaki, Motoaki Chin, Atsushi Sato, Kimikazu Matsumoto, Tsutomu Watanabe, Michiko Kajiwara, Hiroyuki Shimada, Itaru Kato, Yuichi Kodama, Noriko Sato, Kazuko Kudo, Atsushi Kikuta, Megumi Oda, Tomoyuki Watanabe, Akiko M. Saito, Masahito Tsurusawa, Keizo Horibe
Journal: Blood (2011)
Caspofungin for the Treatment of Candidemia in patients with Hematological Malignancies
Authors: Luana Fianchi, Rosa Fanci, Anna Candoni, Morena Caira, Caterina Giovanna Valentini, Brunella Posteraro, Monica Morselli, Giuliana Farina, Maria Enza Mitra, Massimo Offidani, Maurizio Sanguinetti, Maria Elena Tosti, Annamaria Nosari, Pierluigi Viale, Giuseppe Leone, Livio Pagano
Journal: Blood (2008)
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Authors: Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care (2016)

We appreciate the thoughtful comments raised by Agrawal and Gupta (1) on our recent article (2) on the efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. We are pleased that they acknowledge that this study has provided further proof of efficacy of glucagon antagonism as a treatment for type 2 diabetes with acceptable adverse effects at a dose of 30 mg (1). Agrawal and Gupta queried how we arrived at the unequal allocation to the treatment groups with the ratio of 1.5:2.1:1:1 (for 60 mg, 30 mg, 10 mg, and placebo, respectively). Our randomization was probability based and …
Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC)
Authors: L. Marsh, M. Khan, M. Needle, R. Amato
Journal: Journal of Clinical Oncology (2006)

4533 Background: Immunomodulatory drugs are compounds that originated via the deliberate structural modification of thalidomide. Lenalidomide (Revlimid) is a derivative with enhanced immunological and anti-angiogenic properties lacking toxicities associated with thalidomide. Objectives were to determine response rate, time to progression (TTP), one-year survival, and toxicity in patients with progressive MRCC. Methods: Eligibility included: progressive measurable MRCC, adequate organ/marrow function, zubrod performance status (ZPS) ≤ 2, ≤ 1 prior therapy, and no active CNS involvement. Lenalidomide is administered orally at a dose of 25mg daily for 21 days with 7 days rest (28-day cycle), with dose modifications for toxicity. Re-evaluation is done every 3 cycles (12 weeks). RECIST criteria is utilized to determine response rate. TTP is determined from entry into study. Results: 40 pts enrolled. 30 male/10 female, range 38–73 (median 63) years. 38 pts had clear cell carcinoma; 2 pts with papillary. 24 pts received prior immunotherapy and/or chemotherapy. 3 pts met criteria for good prognosis, 33 intermediate and 4 poor. Sites of disease included: lung, nodal, bone, adrenal, kidney, and liver. 17 pts had 1 metastatic site, 13 pts 2 metastatic sites, and 10 pts 3 or more metastatic sites. 36 pts completed at least 12 weeks of therapy. 4 pts had early progressive disease. 1 pt had a CR, 2 pts achieved a PR. 52% of pts had a prolonged TTP ≥ 6 months and 25% ≥ 12 months. Median overall survival of 14.8 months (4.1− 22.2+). Treatment related adverse events included: reversible grade 1/2 non-hematologic toxicity consisting of: nausea, diarrhea, constipation, myalgia and fatigue. 19 pts with grade 3/4 neutropenia and 9 pts with grade 3/4 thrombocytopenia. Median duration of therapy is 6 months (2 - 22). Conclusion: Lenalidomide was well tolerated. Anti-tumor activity has been demonstrated by the following: tumor regression and delayed TTP. The tumor effect was also demonstrated as a second line therapy following cytokine failure. [Table: see text]
[<sup>18</sup>F]fluorothymidine (FLT) PET after 3 days of gefitinib treatment and tumor response in non-small cell lung cancer (NSCLC)
Authors: H. Sohn, S. Kim, J. Ryu, S. Oh, D. Moon, Y. Oh, T. Shim, W. Kim, C. Suh, J. Lee
Journal: Journal of Clinical Oncology (2006)

13031 Background: FLT has been developed as a PET tracer for imaging tumor proliferation. We evaluated whether FLT-PET could predict tumor response only after 3 days of gefitinib treatment. Methods: Nonsmokers with adenocarcinoma of the lung were eligible for this study. FLT-PET was performed at 1 day before and 3 days after the start of gefitinib (250 mg/d) therapy. The maximum standardized uptake value (SUVmax) of the main lung mass was measured, and changes in tumor SUVmax were calculated. After 6 weeks of therapy, response was assessed by chest CT according to WHO criteria. The cutoff value predicting subsequent CT response was obtained by receiver operating characteristic curve analysis. Results: Between Jun. 2005 and Nov. 2005, 22 patients were enrolled. CT response was partial response in 12 (54%), stable disease in 5 (23%), and progressive disease in 5 (23%). As early as 3 days after the initiation of therapy, significant difference in % changes of tumor SUVmax on FLT-PET was observed between responders and nonresponders (−32% v −2.3%, P = .002) ( Table ). When a reduction of tumor SUVmax ≥ 20% was used as a cutoff value for FLT-PET response, CT response could be predicted with positive and negative predictive values of 100% and 83%, respectively. Time to progression was significantly longer in FLT-PET responders than nonresponders (median 5.1 v 1.4 months, P = .011). Conclusions: Using FLT-PET obtained on days 0 and 3 of gefitinib therapy, the response could be early predicted in patients with NSCLC. [Table: see text] No significant financial relationships to disclose.
Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma Undergoing Idiotypic Vaccination
Authors: Maurizio Bendandi, Carlos Becerra, Joseph Kuhn, Suncica Hukic, Nyla Langford, Taizoon Khokhar, Victor Klimyuk, Yuri Gleba, Romy Kandzia, Frank Thieme, Franziska Jarczowski, Jens Uwe Kuenstler, Madhuri Vusirikala, Nora Ku, Robert H. Collins
Journal: Blood (2011)
It is time to stop causing harm with inappropriate imaging for low back pain
Authors: Ben Darlow, Bruce B Forster, Kieran O'Sullivan, Peter O'Sullivan
Journal: British Journal of Sports Medicine (2016)

Inappropriate imaging for low back pain (LBP) can cause harm in three ways: 

1.  Misinterpretation of results by clinicians resulting in unhelpful advice, needless subsequent investigations (downstream testing) and invasive interventions, including surgery;1

2.  Misinterpretation of results by patients resulting in catastrophisation, fear and avoidance of movement and activity, and low expectations of recovery;2

3.  Side effects such as exposure to radiation.3

Problems associated with excessive imaging for LBP are well recognised (http://www.choosingwisely.org) and useful evidence-based guidelines have been developed to help clinicians determine when investigation is appropriate.3 However, currently, 42% of patients with LBP receive an X-ray, CT or MRI within 1 year of diagnosis, and of these, 80% receive imaging within 1 month of presentation.4 The uptake of imaging guidelines is likely to be similarly insufficient among the sports medicine community, where lumbar imaging is frequently used.

As well as recognising when imaging is appropriate, evidence-based reporting and interpretation of imaging findings is critical. The contents of …
Comparison of bevacizumab versus pemetrexed in combination with platinum-based doublets in first-line treatment of advanced non-small cell lung cancer.
Authors: Augusto Akikubo Rodrigues Pereira, Sandro José Martins, Rafael Costa Lessa, Flavio Augusto Ismael Pinto, Debora De Melo Gagliato, Elizabeth S. Santos, Newton Augusto Ferreira Rodrigues, Paulo Henrique Aires Freitas, Fernando Vidigal Padua, Marclesson S. Alves, Geraldine Eltz Lima, Marcello Ferretti Fanelli, Jose A. Rinck, Aldo A. Dettino, Ulisses Ribaldo Nicolau, Jose Rodrigues Pereira, Marcelo Rocha De Sousa Cruz, Vladmir C. Lima
Journal: Journal of Clinical Oncology (2012)

e18078 Background: First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with platinum-based doublets, including pemetrexed (P) or bevacizumab (B), has achieved more than 12 months of survival. At the moment, there are no phase III head-to-head comparisons of these combinations. Methods: We retrospectively analyzed, from 05/2007 to 02/2011, in a single institution, all pts with stage IIIB or IV nonsquamous NSCLC treated with B or P combined with platinum compounds in first-line treatment to determine differences in OS, PFS, ORR and toxicity. We performed multivariate analysis to identify prognostic factors for survival. Results: Of the 82 pts included, 40 pts (48,8%) received carboplatin/paclitaxel or cisplatin/gemcitabine combined with B (BEV group), while 42 pts (51,2%) received cisplatin or carboplatin combined with P (PEM group). BEV had significantly fewer pts with age &gt; 70 years (p=0,01) and CNS metastases (p&lt;0,001) than PEM. Maintenance therapy was administered in 65,0% and 52,4% of pts in BEV and PEM groups, respectively (p=0,17). Significantly more pts in BEV received second-line treatment (72,5% vs. 52,4%; p=0,04) than in PEM, prevailing P as drug of choice (79,3%). ORR (60,0% vs. 35,7%; p=0,04) and median survival (26,4 vs. 16,4 months; p=0,009) were significantly superior for BEV. Median PFS were not different between BEV and PEM (10,5 vs. 7,7 months; p=0,06). In multivariate analysis, ECOG 2 (p=0,005), bone (p=0,01) and adrenal metastases (p=0,005) were independent prognostic factors for worst survival, while treatment with BEV did not reach statistical significance (p=0,07). Grade 3-4 neutropenia (27,5% vs. 9,5%; p=0,03) and neuropathy (17,5% vs. 0%;p=0,005) were more frequent in BEV. Conclusions: First-line treatment of advanced nonsquamous NSCLC patients with platinum-based doublets combined with B resulted in better ORR and higher rate of toxic effects as compared with P-based regimens. ECOG 2, bone and adrenal metastases were independent prognostic factors for poor survival. Although there was a survival benefit at univariate analysis, use of B combination was not an independent prognostic fator.
GW26-e4489 Mesenchymal Stem Cells Engineered with Integrin-Linked Kinase Improves Cardiac Function Paralleled with Enhanced Homing Capacity Following Intracoronary Transplantation in Porcine Myocardial Infarction
Authors: Biao Xu, Dan Mu, Xinlin Zhang, Jun Xie, Bin Zhu
Journal: Journal of the American College of Cardiology (2015)
Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial.
Authors: J. D. Hainsworth, D. R. Spigel, M. S. Rubin, R. V. Boccia, E. P. Fox, I. Firdaus, M. G. Erlander, C. Schnabel, F. A. Greco
Journal: Journal of Clinical Oncology (2010)

10540 Background: Molecular profiling of biopsy specimens identifies a tissue of origin in the majority of CUP patients (pts). However, the value of these diagnoses in improving treatment efficacy is unknown. We present preliminary data from the first prospective evaluation of treatment based on molecular assay diagnoses in CUP pts. Methods: Surgical or core needle biopsies from previously untreated CUP pts were submitted for determination of a primary site by a 92-gene RT-PCR assay (CancerTYPE ID, bioTheranostics, Inc). Pts received standard first-line therapy for the cancer identified; pts unclassifiable by assay received empiric paclitaxel/carboplatin/bevacizumab/erlotinib. Study goals: 1) to evaluate the ability of the CancerTYPE ID assay to identify the tissue of origin in a prospective, unselected group of CUP pts, and 2) to obtain information regarding efficacy of assay-directed treatment. Results: Between 10/08 and 8/09, 110 pts were enrolled, and 66 received assay-directed therapy. 44 pts did not receive assay-directed treatment: became ineligible -15, insufficient tissue – 12, refused assay-directed treatment -8, required treatment prior to assay results – 7, assay results led to primary site detection - 2. Diagnoses were made in 61 of 66 pts (92%) and included: pancreas – 11, colorectal – 8, urinary bladder – 8, NSCLC – 5, ovary – 4, breast – 3, kidney – 3, gallbladder – 3, liver – 3, carcinoid – 3, skin (squamous) – 3, others – 7 (1 each). ORR and median PFS for the entire group were 32% and 7.4 months, respectively. The 8 colorectal cancer pts had typical distribution of metastases (liver, intra-abdominal) and had clinical benefit with FOLFOX/bevacizumab (3 PR, 5 SD). In other diagnostic groups, clinical features and response to treatment were generally as expected. Updated efficacy information on subgroups will be presented. Conclusions: Molecular profiling predicted a tissue of origin in most pts with CUP. Clinical features were generally consistent with the assay diagnosis, as were responses to directed therapy. These preliminary data are promising, and the study is ongoing to better evaluate the impact of molecular profiling on treatment outcomes. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biotheranostics Biotheranostics, Genentech Biotheranostics Biotheranostics
Rituximab Added to Aggressive Chemotherapy Improves the Outcome of Patients with Follicular Lymphoma, Grade 3 and Results In Survival Comparable to Diffuse Large B-Cell Lymphoma.
Authors: Philip J. Bierman, Julie M. Vose, R. Gregory Bociek, Fausto R. Loberiza, Martin Bast, James O. Armitage
Journal: Blood (2010)
Survival and cost‐effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database
Authors: Neehar D. Parikh, Vincent D. Marshall, Amit G. Singal, Hari Nathan, Anna S. Lok, Rajesh Balkrishnan, Vahakn Shahinian
Journal: Hepatology (2016)

Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC). However, its effectiveness in patients with Child-Pugh class B cirrhosis and any moderating effects of health system characteristics are unclear. We examined the survival and cost-effectiveness associated with sorafenib in elderly patients with advanced HCC. We performed an analysis of Medicare beneficiaries with HCC diagnoses from 2007 to 2009. We compared advanced stage patients with HCC (American Joint Committee on Cancer stage III/IV) who received sorafenib within 6 months of diagnosis (and were otherwise untreated) to advanced stage patients with HCC who received no therapy (control). We performed univariate and multivariate analyses to identify predictors of survival. Incremental cost-effectiveness ratios (ICERs) were calculated for sorafenib-treated and control patients. We included 228 sorafenib-treated patients and 870 control patients. The median survival of the sorafenib-treated patients was 150.5 days versus 62 days for control patients. On multivariate analysis, significant predictors of improved survival were treatment with sorafenib (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.57-0.77), being seen at a National Cancer Institute-designated cancer center (HR, 0.77; 95% CI, 0.62-0.97), and being seen at a transplantation center (HR, 0.77; 95% CI, 0.65-0.93). Predictors of worse survival included stage IV disease (HR, 1.40; 95% CI, 1.24-1.58), decompensated cirrhosis (HR, 1.49; 95% CI, 1.30-1.70), and treatment in an urban setting (HR, 1.45; 95% CI, 1.21-1.73.) Although sorafenib use was associated with a survival benefit (HR, 0.61; 95% CI, 0.47-0.79) among patients with decompensated cirrhosis, the median survival benefit was 31 days, and it was not cost-effective (ICER, $224,914 per life year gained).Sorafenib is associated with improved survival in elderly patients with advanced HCC; however, it is not cost-effective among those with hepatic decompensation. (Hepatology 2017;65:122-133).
Normal Circulating B Cells Are Markedly Reduced in Follicular Lymphoma and Diffuse Large B Cell Lymphoma at Diagnosis
Authors: Massimo Geuna, Bruna Riccardo, Alessandro Cignetti, Nathalie Santoro, Angela Gueli, Angela Rita Elia, Giuseppina Prato, Giovanni De Rosa, Mauro Papotti, Corrado Tarella
Journal: Blood (2014)
Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence.
Authors: C. Jouannaud, J. Charpentier, I. Van Praagh-Doreau, J. Eymard, X. Durando, P. J. Chollet, E. Brabencova, J. Nabholtz, H. Cure, F. Penault-Llorca
Journal: Journal of Clinical Oncology (2010)

620 Background: Pathological responses rates will be studied comparatively in 264 women with stage II-IIIA operable BC randomized to receive either 3 courses of FEC100 followed by 3 courses of taxotere 100 mg/m2 (standard arm A) or the same protocols according to the tumor evaluation after 2 and 4 courses (adapted arm B). Patients are shifted to taxotere if response is less than 30% after 2 FEC100 or 50% after 4 FEC100; otherwise the first protocol is continued until six courses before surgery. In order to reach an intermediate analysis, a pathological review is conducted to assess the residual disease in breast and nodes according to Chevallier's classification (Am J Clin Oncol 1993) in patients repartited according to 2 tumour phenotypes: Her2-HR+ (hormonal receptor; luminal phenotype) and Her2-HR- (triple-negative phenotype). Methods: 90 patients have been randomized to date with a mean age of 52.8 years. 70 patients have finished their treatment (54 T2, 16 T3; 40 N0, 30 N1). 48 patients had positive HR and 14 were triple negative. The median number of NCT courses was 6 and most patients were shifted to taxotere at least after 4 courses. Results: PCR was 16% (5/31 patients) but overall 45% of patients presented with an important alteration of the tumoral structure with residual disease of minor importance, and minimal axillary invasion. The pCR rate (Chevallier's classes 1+2) was higher in triple negative phenotype than in luminal phenotype. As pCR frequence decreases presently due to more extensive pathological examinations, we decided to establish a new pathological classification taking better in consideration the limited residual disease in breast and nodes, and to establish prospectively its prognostic value. Results will be updated at the meeting, and the value of the new classification of residual disease discussed. Conclusions: This randomized prospective trial aims to establish the value of induction chemotherapy tailored according to response, and to result in a better classification of the residual disease. No significant financial relationships to disclose.